The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity

Journal of Surgical Research

Volumn 125, Issue 2, 2005, Pages 137-143

  Brook, Nicholas R ^a,b   Waller, Julian R ^a   Bicknell, Gareth R ^a   Nicholson, Michael L ^a  

^a Surgery Department Dick White Referrals   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Calcineurin inhibitor; Collagen; Gene expression; Immunosuppression; Matrix metalloproteinases; Nephrotoxicity; Pirfenidone; Tacrolimus

Indexed keywords

COLLAGEN TYPE 3; CREATININE; GELATINASE A; GELATINASE B; MESSENGER RNA; PIRFENIDONE; PROTEIN; SODIUM CHLORIDE; TACROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; GENETIC ANALYSIS; KIDNEY FIBROSIS; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT;

EID: 18044370861     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.12.007     Document Type: Article

References (54)

1. H.A. Kries, C. Ponticelli Causes of late allograft loss Chronic allograft dysfunction, death, and other factors Transplantation 71 2001 SS5
2. W.M. Bennett, A.M. de Mattos, M. Meyer, T. Andoh, J.M. Barry Chronic cyclosporine nephropathy The Achilles' heel of immunosuppressive therapy Kidney Int. 50 1996 1089
3. F.S. Shihab, W.M. Bennett, A.M. Tanner, T.F. Andoh Mechanism of fibrosis in experimental tacrolimus nephrotoxicity Transplantation 64 1997 1829
4. P.S. Randhawa, R. Shapiro, M.L. Jordan, T.E. Starzl, A.J. Demetris The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine Am. J. Surg. Pathol. 17 1993 60
5. T.F. Andoh, E.A. Burdmann, J. Lindsley, D.C. Houghton, W.M. Bennett Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model Transplantation 57 1994 483
6. Japanese FK 506 Study Group Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Transplant. Proc. 25 1993 624
7. S. Rosen, Z. Greenfeld, M. Brezis Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury Transplantation 49 1990 445
8. T.F. Andoh, E.A. Burdmann, J. Lindsley, D.C. Houghton, W.M. Bennett Functional and structural characteristics of experimental FK 506 nephrotoxicity Clin. Exp. Pharmacol. Physiol. 22 1995 646
9. S.B. Margolin, S. Lefkowitz Pirfenidone A novel pharmacological agent for the prevention and resolution (removal) of lung fibrosis FASEB J. 8 1994 A117 [abstract]
10. H. Suga, S. Teraoka, K. Ota Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats Exp. Toxicol. Pathol. 47 1995 287
11. S.N. Iyer, J.S. Wild, M.J. Schiedt Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters J. Lab. Clin. Med. 125 1995 779
12. L.L. Hall, G.R. Bicknell, L. Primrose Reproducibility in the quantifcation of mRNA levels by RT-PCR-ELISA and RT competitive-PCR-ELISA Biotechniques 24 1998 652
13. G.R. Bicknell, J.A. Shaw, J.H. Pringle, P.N. Furness Amplication of specific mRNA from a single human renal glomerulus, with an approach to the separation of epithelial cell mRNA J. Pathol. 180 1996 188
14. G.R. Bicknell, S.T. Williams, J.A. Shaw Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants Br. J. Surg. 87 2000 1569
15. P.N. Furness The use of digital images in pathology J. Pathol. 183 1997 253
16. M.L. Nicholson, E. Bailey, S. Williams, K.P. Harris, P.N. Furness Computerised histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of rejection Transplantation 68 1999 236
17. A.D. Mayer, J. Dmitrewski, J.P. Squifflet Multicentre randomised trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection Transplantation 64 1997 436
18. J.D. Pirsch, J. Miller, M.H. Deierhoi, F. Vincenti, R.S. Filo A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group Transplantation 63 1997 977
19. R. Margreiter Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation A randomised multicentre study Lancet 359 2002 741
20. R. Trompeter, G. Filler, N.J. Webb Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation Pediatr. Nephrol. 17 2002 141
21. G.A. Knoll, R.C. Bell Tacrolimus versus cyclosporin for immunosuppression in renal transplantation Meta-analysis of randomised trials BMJ 318 1999 1104
22. F. Vincenti, S.C. Jensik, R.S. Filo, J. Miller, J. Pirsch A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation Evidence for improved allograft survival at five years Transplantation 73 2002 775
23. A.D. Mayer Chronic rejection and graft half-life Five-year follow-up of the European Tacrolimus Multicenter Renal Study Transplant. Proc. 34 2002 1491
24. K. Baboolal, G.A. Jones, A. Janezic, D.R. Griffiths, W.A. Jurewicz Molecular and structural consequences of early renal allograft injury Kidney Int. 61 2002 686
25. S. Jain, G.R. Bicknell, M.L. Nicholson Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury Br. J. Surg. 87 2000 1563
26. M.L. Nicholson, S.J. Harper, T.J. Wheatley Renal transplant fibrosis Histomorphometric assessment of early renal transplant biopsies for markers of chronic rejection Transplant. Proc. 29 1997 2793
27. P.N. Furness Histolpathology of chronic renal allograft dysfunction Transplantation 71 2001 SS31
28. P.N. Furness Extracellular matrix and the kidney Clin. Pathol. 49 1996 355
29. M. Davies, J. Martin, G.J. Thomas, D.H. Lovett Proteinases and glomerular matrix turnover Kidney Int 41 1992 671
30. A. Heidland, K. Sebekova, L. Paczek Renal fibrosis Role of impaired proteolysis and potential therapeutic strategies Kidney Int. 52 1997 S32
31. R.A. Ignotz, T. Endo, J. Massagué Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β J. Biol. Chem. 262 1987 6643
32. B. Ryffel, E. Weber, M.J. Mihatsch Nephrotoxicity of immunosuppressants in rats Comparison of macrolides with cyclosporin Exp. Nephrol. 2 1994 324
33. J. Kopp, P.E. Klotman Cellular and molecular mechanisms of cyclosporine nephrotoxicity J. Am. Soc. Nephrol. 1 1990 162
34. L.W. Elzinga, S. Rosen, W.M. Bennett Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy Role of sodium intake J. Am. Soc. Nephrol. 4 1993 214
35. M.J. Mihatsch, B. Ryffel, F. Gudat The differential diagnosis between rejection and cyclosporine toxicity Kidney Int. 48 Suppl 1995 S63
36. A. Khanna, V. Cairns, J.D. Hosenpud Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells Transplantation 67 1999 614
37. G.T. Shin, A. Khanna, R. Ding In vivo expression of transforming growth factor β1 in humans Stimulation by cyclosporine Transplantation 65 1998 313
38. M.A. Mohamed, H. Robertson, T.A. Booth TGF-beta expression in renal transplant biopsies A comparative study between cyclosporin-A and tacrolimus Transplantation 69 2000 1002
39. A.A. Eddy, C.A. Giachelli, L. McCulloch, E. Lim Renal expression of genes that promote interstital inflammation and fibrosis in rats with protein overloaded proteinuria Kidney Int. 47 1995 1546
40. C. Duymelinck, J.T. Deng, M.E. de Broe Expression of TIMP-1 mRNA and PAI-1 protein is unregulated in renal fibrotic areas after cyclosporine (CsA) treatment J. Am. Soc. Nephrol. 8 1997 600
41. W. Mo, C. Brecklin, S.L. Garber Changes in collagenases and TGF-β precede structural alterations in a model of chronic renal fibrosis Kidney Int. 56 1999 145
42. J.R. Waller, G.R. Bicknell, M.L. Nicholson Sirolimus attenuates the expression of metalloproteinase-2 and -9 and inhibits intimal hyperplasia following balloon angioplasty Transplant. Proc. 34 2002 2881
43. J.R. Waller, G.J. Murphy, G.R. Bicknell Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats Eur. J. Vasc. Endovasc. Surg. 23 2002 234
44. M.L. Nicholson, J.R. Waller, G.R. Bicknell Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA Br. J. Surg. 89 2002 933
45. A. Dosanjh, T. Ikonen, B. Wan, R.E. Morris Pirfenidone A novel anti-fibrotic agent and progressive chronic allograft rejection Pulm. Pharmacol. Ther. 15 2002 433
46. T. Shimizu, T. Kuroda, S. Hata Pirfenidone improves renal function and fibrosis in the post-obstructed kidney Kidney Int. 54 1998 99
47. M.A. Al Bayati, Y. Xie, F.C. Mohr, S.B. Margolin, S.N. Giri Effect of pirfenidone against vanadate-induced kidney fibrosis in rats Biochem. Pharmacol. 64 2002 517
48. A. Di Sario, E. Bendia, G. Svegliati Baroni Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production J. Hepatol. 37 2002 584
49. S.N. Iyer, G. Gurujeyalakshmi, S.N. Giri Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J. Pharmacol. Exp. Ther. 289 1999 211
50. S. Mirkovic, A.M. Seymour, A. Fenning Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats Br. J. Pharmacol. 135 2002 961
51. L. Garcia, I. Hernandez, A. Sandoval Pirfenidone effectively reverses experimental liver fibrosis J. Hepatol. 37 2002 797
52. T. Shimizu, M. Fukagawa, T. Kuroda Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy Kidney Int. Suppl. 63 1997 S239
53. B.S. Lee, S.B. Margolin, R.A. Nowak Pirfenidone A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production J. Clin. Endocrinol. Metab. 83 1998 219
54. M. Corbel, J. Lanchou, N. Germain Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice Eur. J. Pharmacol. 426 2001 113